The global pulmonary arterial hypertension treatment market is on track to achieve significant growth over the next decade, with a projected valuation of USD 7,224.4 million by 2033. This expansion ...
To protect your loved one, please do not visit if you are sick or have a COVID-19 positive test result. Get more resources on masking and COVID-19 precautions. Congenital pulmonary stenosis is a ...
and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered ...
About Pulmonary Arterial Hypertension (PAH ... of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment ...
Liquidia has also obtained certain rights to Pharmosa’s next-generation smart-technology nebulizers for use with ... to research and development in pulmonary hypertension. This partnership ...